V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

EUROPEAN COMMISSION

Prior notification of a concentration

(Case M.10215 — CVC/Carlyle/MedRisk)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 139/05)

1. On 13 April 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— CVC Capital Partners SICAV-FIS S.A. ('CVC', Luxembourg),

— The Carlyle Group, Inc. ('Carlyle', United States),

— MedRisk Holdco, LLC ('MedRisk', United States), controlled by Carlyle.

CVC and Carlyle acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of MedRisk.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for CVC: management of investment funds and platforms holding interests in companies active in various industries primarily in Europe, United States, and the Asia-Pacific region,

— for Carlyle: global alternative asset manager of funds active globally across different investment disciplines, including corporate private equity, real estate, and natural resources funds,

— for MedRisk: supplier of managed physical therapy for the workers' compensation industry and related market sectors in the United States.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for the treatment of certain concentrations under Council Regulation (EC) No 139/2004, ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').
([2]) OJ C 366, 14.12.2013, p. 5.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10215 — CVC/Carlyle/MedRisk

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË